Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Current Liabilities: 2015-2024

Historic Total Current Liabilities for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $41.2 million.

  • Seres Therapeutics' Total Current Liabilities fell 65.40% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year decrease of 65.40%. This contributed to the annual value of $41.2 million for FY2024, which is 58.22% down from last year.
  • Seres Therapeutics' Total Current Liabilities amounted to $41.2 million in FY2024, which was down 58.22% from $98.7 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Total Current Liabilities registered a high of $98.7 million during FY2023, and its lowest value of $41.2 million during FY2024.
  • Its 3-year average for Total Current Liabilities is $75.2 million, with a median of $85.6 million in 2022.
  • In the last 5 years, Seres Therapeutics' Total Current Liabilities surged by 77.22% in 2021 and then crashed by 58.22% in 2024.
  • Over the past 5 years, Seres Therapeutics' Total Current Liabilities (Yearly) stood at $46.4 million in 2020, then surged by 77.22% to $82.3 million in 2021, then grew by 4.06% to $85.6 million in 2022, then climbed by 15.26% to $98.7 million in 2023, then tumbled by 58.22% to $41.2 million in 2024.